194 related articles for article (PubMed ID: 2690330)
1. Omeprazole: pharmacokinetics and metabolism in man.
Cederberg C; Andersson T; Skånberg I
Scand J Gastroenterol Suppl; 1989; 166():33-40; discussion 41-2. PubMed ID: 2690330
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome.
Vinayek R; Amantea MA; Maton PN; Frucht H; Gardner JD; Jensen RT
Gastroenterology; 1991 Jul; 101(1):138-47. PubMed ID: 2044903
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and metabolism of omeprazole in animals and man--an overview.
Regårdh CG; Gabrielsson M; Hoffman KJ; Löfberg I; Skånberg I
Scand J Gastroenterol Suppl; 1985; 108():79-94. PubMed ID: 3858978
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses.
Regårdh CG; Andersson T; Lagerström PO; Lundborg P; Skånberg I
Ther Drug Monit; 1990 Mar; 12(2):163-72. PubMed ID: 2315973
[TBL] [Abstract][Full Text] [Related]
5. Effect of single and repeated intravenous doses of omeprazole on pentagastrin stimulated gastric acid secretion and pharmacokinetics in man.
Jansen JB; Lundborg P; Baak LC; Greve J; Ohman M; Stöver C; Röhss K; Lamers CB
Gut; 1988 Jan; 29(1):75-80. PubMed ID: 3343017
[TBL] [Abstract][Full Text] [Related]
6. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.
Tassaneeyakul W; Vannaprasaht S; Yamazoe Y
Br J Clin Pharmacol; 2000 Feb; 49(2):139-44. PubMed ID: 10671908
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of lansoprazole.
Landes BD; Petite JP; Flouvat B
Clin Pharmacokinet; 1995 Jun; 28(6):458-70. PubMed ID: 7656504
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of various single intravenous and oral doses of omeprazole.
Andersson T; Cederberg C; Regårdh CG; Skånberg I
Eur J Clin Pharmacol; 1990; 39(2):195-7. PubMed ID: 2253676
[TBL] [Abstract][Full Text] [Related]
9. Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo.
Larsson H; Mattson H; Sundell G; Carlsson E
Scand J Gastroenterol Suppl; 1985; 108():23-35. PubMed ID: 3858975
[TBL] [Abstract][Full Text] [Related]
10. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate.
Sharma VK; Peyton B; Spears T; Raufman JP; Howden CW
Aliment Pharmacol Ther; 2000 Jul; 14(7):887-92. PubMed ID: 10886044
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects.
Andersson T; Andrén K; Cederberg C; Lagerström PO; Lundborg P; Skånberg I
Br J Clin Pharmacol; 1990 May; 29(5):557-63. PubMed ID: 2350532
[TBL] [Abstract][Full Text] [Related]
12. Omeprazole: pharmacology, pharmacokinetics and interactions.
Oosterhuis B; Jonkman JH
Digestion; 1989; 44 Suppl 1():9-17. PubMed ID: 2691315
[TBL] [Abstract][Full Text] [Related]
13. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.
Hartmann M; Theiss U; Huber R; Lühmann R; Bliesath H; Wurst W; Lücker PW
Aliment Pharmacol Ther; 1996 Jun; 10(3):359-66. PubMed ID: 8791964
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic evaluation of omeprazole suspension following oral administration in rats: effect of neutralization of gastric acid.
Watanabe K; Matsuka N; Furuno K; Eto K; Kawasaki H; Gomita Y
Acta Med Okayama; 1996 Aug; 50(4):219-22. PubMed ID: 8874584
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability and efficacy of omeprazole given orally and by nasogastric tube.
Larson C; Cavuto NJ; Flockhart DA; Weinberg RB
Dig Dis Sci; 1996 Mar; 41(3):475-9. PubMed ID: 8617118
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of proton pump inhibitors in children.
Litalien C; Théorêt Y; Faure C
Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
[TBL] [Abstract][Full Text] [Related]
17. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients.
Cederberg C; Thomson AB; Mahachai V; Westin JA; Kirdeikis P; Fisher D; Zuk L; Marriage B
Gastroenterology; 1992 Sep; 103(3):913-8. PubMed ID: 1499942
[TBL] [Abstract][Full Text] [Related]
18. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole.
Hurlimann S; Abbühl B; Inauen W; Halter F
Aliment Pharmacol Ther; 1994 Apr; 8(2):193-201. PubMed ID: 8038351
[TBL] [Abstract][Full Text] [Related]
19. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer.
Ching MS; Mihaly GW; Angus PW; Morgan DJ; Devenish-Meares S; Yeomans ND; Smallwood RA
Br J Clin Pharmacol; 1991 Feb; 31(2):166-70. PubMed ID: 2049231
[TBL] [Abstract][Full Text] [Related]
20. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.
Sohn DR; Kobayashi K; Chiba K; Lee KH; Shin SG; Ishizaki T
J Pharmacol Exp Ther; 1992 Sep; 262(3):1195-202. PubMed ID: 1527724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
